Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus

Aim.
To assess expedience of metformin combination with long-acting insulin, determine optimal doses of metformin for patients with type 2 diabetesmellitus (DM2), and accomplish pharmacoeconomic analysis of clinical efficiency of various therapeutic modalities.
Materials and methods.
Patients with decompensated DM2 (n=126) were under observation for 1 year during which they received rational hypoglycemictherapy with metformin and long-acting insulin (LAI) at bedtime, with the dose being titrated until the desired level of glycemic control wasachieved. The patients were randomly allocated to the following 3 groups: group 1 (sulponylurea derivatives (SUD), LAI, and metformin at a doseof 1000 mg b.i.d.), group 2 (SUD, LAI, and metformin at 500 mg b.i.d.), group 3 (SUD and LAI). In case of postprandial glycemia >9 mmol/l at amaximum dose of SUD, it was replaced by short-acting insulin. Cost-effectiveness analysis of different therapeutic regimes was performed.
Results.
The cost of examination and treatment of patients given SUD and LAI in combination with metformin at a daily dose of 2000 mg to achievethe desired quality of glycemic control was lower compared with two other groups. Moreover, this therapy was most efficacious and ensured the desiredlevel of glycemic control in a greater number of patients. Cost-effectiveness analysis confirmed advantages of this treatment.
Conclusion.
Combined hypoglycemic therapy with SUD, LAI, and metformin (200 mg daily) has the advantage of lowest cost and maximum efficiencycompared with other modalities.

metformin, insulin therapy, combined therapy, pharmacoeconomic analysis

1. Aviles-Santa L., Sinding J., Raskin P.: Effects of metformin in patients with poorly controlled, insulin- treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial// Ann Intern Med.-1999- №131.- P.182-188.

2. Wulffele M.G., Kooy A., Lehert Ph., Bets D., Jeles C.O., Borger van der Burg B., Donker Ab., Stehouwer C.// Сombination of insulin and metformin in the treatment of type 2 diabetes//Diabetes Care. - 2002. - №25.- P. 2133-2140.

3. Chaudhury A., Tomar R., Mohanty P. The combination of insulin and metformin in treatment of non - insulin - dependent diabetes mellitus// Endocr Pract. - 1998. - №4(5). - P. 259-67.

4. Fritsche A., Stumvoll M. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients// Acta Diabetol. - 2000. - №37(1). - Р. 13-8.

5. Strowing S.M., Aviles - Santa M.L. and Raskin P. Comparison of insulinotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes// Diabetes Care. - 2002. - №25. - P. 1691-1698.

6. Ponssen H.H., Elte J.W. Combined metformin and insulin therapy for patients with patients with type 2 diabetes mellitus//Clin Ther. - 2000 - №22(6). - P. 709-718.

7. Hermann L.S., Katzman P., Lager I., Nilsson A., Sartor G. Long - term glycaemic improvement after addition of metformin to insulin in insulin - treated obese type 2 diabetes patients// Diabetes Obes Metab. - 2001. - № 3(6). - P. 428-434.

8. Авксентьева М.В., Воробьев П.А., Герасимов В.Б. и др. Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ) М.:Ньюдиамед, - 2000. - 80 с.

9. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Журн. Проблемы стандартизации в здравоохранении. - 2002. -№5. - с. 55-67.

10. Основы клинической фармакологии и рациональной фармакотерапии. Руководство для практикующих врачей. Под общ. ред. Ю. Б. Белоусова, М. В. Леоновой. - М. Бионика - 2002 - с. 368.